Randomized trial · people
Pramlintide: 3.7% placebo-corrected weight loss at 16 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this short trial, pramlintide alone, without a lifestyle program, led to modest weight loss beyond placebo in people with obesity, and the loss did not depend on having nausea.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 204
- Published
- 2007
- Journal
- J Clin Endocrinol Metab
What they tested
The team tested whether pramlintide, at doses higher than earlier studies used, lowers body weight in people with obesity, and how safe and tolerable it is.
How the study was done
A phase 2 randomized, double-blind, placebo-controlled trial at several centers in 204 adults with obesity, with or without type 2 diabetes, none using insulin. For 16 weeks they injected pramlintide or placebo (a dummy shot) under the skin three times a day before meals, with the dose stepped up to as much as 240 microg, and no diet or exercise program added.

Model. Individual results vary.
What they found
People who finished 16 weeks on pramlintide lost 3.7 ± 0.5% of body weight (3.6 ± 0.6 kg) and 3.6 ± 1.1 cm of waist size beyond what the placebo group lost. About 31% of the pramlintide group lost at least 5% of their weight, compared with 2% on placebo. In all, 88% reached the 240 microg dose, and dropout was 29% on pramlintide vs 25% on placebo. The most common side effect was mild nausea that passed, and weight loss was similar in people with nausea (3.9 ± 0.5%) and without it (3.6 ± 0.5%).
What it doesn’t show
This was a short, 16-week phase 2 trial, and the weight results are for people who completed it, while about a quarter or more of each group dropped out. It doesn't show whether the weight loss lasts or grows over a longer time.
The paper
Aronne et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007.
The compound
More studies on Pramlintide
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinMeta-analysis · people · 2003
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose groupRandomized trial · people · 2023
- Pramlintide: weight loss maintained over 12 months in obesityRandomized trial · people · 2008
- Pramlintide lowered post-meal glucagon and glucose in type 2 diabetesRandomized trial · people · 2002
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.